IDH1 and central nervous system cancer: The safety, tolerability, and immunogenicity of the IDH1-vac vaccine in combination with the immune checkpoint inhibitor avelumab (AVE) in patients with IDH1R132H-mutant gliomas are being examined in the AMPLIFY-NEOVAC study (NCT03893903).